ORIC®Pharmaceuticals Initiates Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat In Combination With NUBEQA
Benzinga Newsdesk 3 months ago
BiotechGeneralNews
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abirateroneEntered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone
Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1